Harvard Bioscience (HBIO) Total Liabilities (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Total Liabilities data on file, last reported at $67.9 million in Q1 2026.

• Quarterly Total Liabilities rose 4.5% year-over-year to $67.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.9 million (up 4.5% YoY) and the FY2025 annual result came in at $66.3 million, up 4.79% from the prior year.
• Total Liabilities rose to $67.9 million in Q1 2026 per HBIO's latest filing, from $66.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $81.7 million in Q1 2022 and bottomed at $61.7 million in Q2 2024.
• The 5-year median for Total Liabilities is $65.9 million (2024), against an average of $68.2 million.
• The widest annual swing landed in 2022, when Total Liabilities advanced 10.16%; it then declined 13.19% in 2023.
• Tracing HBIO's Total Liabilities over 5 years: stood at $73.1 million in 2022, then dropped by 12.1% to $64.3 million in 2023, then retreated by 1.54% to $63.3 million in 2024, then increased by 4.79% to $66.3 million in 2025, then increased by 2.34% to $67.9 million in 2026.
• Per Business Quant, the three latest HBIO Total Liabilities figures stand at $67.9 million (Q1 2026), $66.3 million (Q4 2025), and $63.9 million (Q3 2025).

Peer Comparison